Promoter Methylation and Expression Status of Cytotoxic T-Lymphocyte-Associated Antigen-4 Gene in Patients with Lupus

Document Type : Original Article


1 Department of internal medicine, Zahean university of medical science, Zahedan, Iran

2 Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran


Objectives: Systemic lupus erythematous (SLE) is an autoimmune disease with both genetic susceptibility and epigenetic modifications. Autoantibodies directly contribute to the destruction of some organs such as kidneys, joints, skin, lungs, central nervous system, and blood-forming (hematopoietic) system. The CTLA4 plays an important role in inhibition of the activity of T cells and preventing autoimmune disorders, for example; the lupus. We analyzed the promoter methylation, polymorphism, and expression status in CTLA4 gene in patients with lupus. Methods: Genomic DNA was isolated from 50 individuals’ blood samples with SLE and 50 control participants. CTLA4 gene polymorphisms analysis in polymorphic site, -318(CT) and +49(AG), was done by Tetra-ARMS-PCR. Methylation-specific polymerase chain reaction (MS-PCR) was used to estimate promoter hyper methylation of the CTLA4 gene. The present paper also analyzed CTLA4 mRNA levels in 30 blood samples from the intended participants, and healthy control by real-time PCR. Results: Changes in promoter methylation of CTLA4 gene were remarkably different in patients with lupus than healthy controls (OR= 0.48; 95% CI= 0.1959, 1.202; P-value= 0.005). However, gene expression level of CTLA4 was not statistically different in patients than the healthy control group. Conclusions: This epigenetic study gives us an overview of the role of CTLA4 promoter methylation in pathogenesis of SLE, which cause preventing its expression. As we know CTLA4 has the role in immune regulation and downregulates immune responses. In the future a comprehensive understanding of the epigenetic mechanisms contributing to SLE will likely enable development of new therapeutic agents and strategies that target the dysregulated genes or correct the aberrant epigenetic modifications (Epigenetic therapies for SLE).


Achtman, J. C., & Werth, V. P. (2015). Pathophysiology of cutaneous lupus erythematosus. Arthritis research & therapy, 17(1), 182.
Altorok, N., & Sawalha, A. H. (2013). Epigenetics in the pathogenesis of systemic lupus erythematosus. Current opinion in rheumatology, 25(5), 569-576.
Ballestar, E., Esteller, M., & Richardson, B. C. (2006). The epigenetic face of systemic lupus erythematosus. The Journal of Immunology, 176(12), 7143-7147.
Bengtsson, A., & Rönnblom, L. (2017). Systemic lupus erythematosus: still a challenge for physicians. Journal of internal medicine, 281(1), 52-64.
Cojocaru, M., Cojocaru, I. M., Silosi, I., & Vrabie, C. D. (2011). Manifestations of systemic lupus erythematosus. Maedica, 6(4), 330.
Cunningham, M., & Gilkeson, G. (2011). Estrogen receptors in immunity and autoimmunity. Clinical reviews in allergy & immunology, 40(1), 66-73.
Dariavach, P., Mattéi, M. G., Golstein, P., & Lefranc, M. P. (1988). Human Ig superfamily CTLA‐4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA‐4 cytoplasmic domains. European journal of immunology, 18(12), 1901-1905.
Davatchi, F., Jamshidi, A.-R., Banihashemi, A. T., Gholami, J., Forouzanfar, M. H., Akhlaghi, M., . . . Salesi, M. (2008). WHO-ILAR COPCORD study (stage 1, urban study) in Iran. The Journal of rheumatology, 35(7), 1384-1390.
Foster, M. H. (2007). T cells and B cells in lupus nephritis. Paper presented at the Seminars in nephrology.
Ghodke-Puranik, Y., & Niewold, T. B. (2015). Immuno- genetics of systemic lupus erythematosus: a comprehensive review. Journal of autoimmunity, 64, 125-136.
Grimaldi, C. M. (2006). Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Current opinion in rheumatology, 18(5), 456-461.
Harley, I. T., Kaufman, K. M., Langefeld, C. D., Harley, J. B., & Kelly, J. A. (2009). Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nature Reviews Genetics, 10(5), 285.
Iraji, R., Arish, M., Aminifard, M., & Dianat, T. (2019). Expression and promoter-hyper methylation analysis of MGMT gene in patients with pterygium. Journal of Epigenetics, doi: 10.22111/jep.2019.28421.1009, 1(2), 1-8.
Javierre, B. M., Fernandez, A. F., Richter, J., Al-Shahrour, F., Martin-Subero, J. I., Rodriguez-Ubreva, J., . . . Rider, L. G. (2009). Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome research.
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., . . . Hughes, G. (2016). Systemic
lupus erythematosus. Nature Reviews Disease Primers, doi:10.1038/nrdp.2016.39,  2, 16039.
Kordi-Tamandani, D. M., Vaziri, S., Dahmardeh, N., & Torkamanzehi, A. (2013). Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia. Molecular biology reports, 40(8), 5123-5128.
Liu, Z., & Davidson, A. (2012). Taming lupus—a new understanding of pathogenesis is leading to clinical advances. Nature medicine, 18(6), 871.
Lu, Q., Kaplan, M., Ray, D., Ray, D., Zacharek, S., Gutsch, D., & Richardson, B. (2002). Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis & Rheumatism, 46(5), 1282-1291.
Maidhof, W., & Hilas, O. (2012). Lupus: an overview of the disease and management options. Pharmacy and Therapeutics, 37(4), 240.
Mohan, C., & Putterman, C. (2015). Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nature Reviews Nephrology, 11(6), 329.
Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A., & Herrmann, M. (2010). The role of defective clearance of apoptotic cells in systemic autoimmunity. Nature Reviews Rheumatology, 6(5), 280.
Niewold, T. B. (2015). Advances in lupus genetics. Current opinion in rheumatology, 27(5), 440.
Patel, D. R., & Richardson, B. C. (2010). Epigenetic mechanisms in lupus. Current opinion in rheumatology, 22(5).
Relle, M., Weinmann-Menke, J., Scorletti, E., Cavagna, L., & Schwarting, A. (2015). Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmunity Reviews, 14(11), 1005-1018.
Schur, P. (1995). Genetics of systemic lupus erythematosus. Lupus, 4(6), 425-437.
Sestak, A. L., Fürnrohr, B. G., Harley, J. B., Merrill, J. T., & Namjou, B. (2011). The genetics of systemic lupus erythematosus and implications for targeted therapy. Annals of the Rheumatic Diseases, 70(Suppl 1), i37-i43.
Shao, W.-H., & Cohen, P. L. (2011). Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis research & therapy, 13(1), 202.
Shelly, S., Boaz, M., & Orbach, H. (2012). Prolactin and autoimmunity. Autoimmunity Reviews, 11(6-7), A465-A470.
Shojaa, M., Aghaie, M., Khashayar, P., Amoli, M., Qorbani, M., & Mohammadi, Z. (2015). The survey of association between Polymorphism of CTLA-4 Exon 1 with Systemic Lupus Erythematosus. Armaghane Danesh Bimonthly Journal, 19(10), 893-901.
Vyse, T., & Kotzin, B. (1998). Genetic susceptibility to systemic lupus erythematosus. Annual review of immunology, 16(1), 261-292.
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., . . . Mavroukakis, S. (2007). Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of immunotherapy (Hagerstown, Md.: 1997), 30(8), 825.
Zhan, Y., Guo, Y., & Lu, Q. (2016). Aberrant Epigenetic Regulation in the Pathogenesis of Systemic Lupus Erythematosus and Its Implication in Precision Medicine. Cytogenetic and genome research, 149(3), 141-155.
Volume 2, Issue 1
January 2021
Pages 31-38
  • Receive Date: 03 November 2019
  • Revise Date: 01 November 2020
  • Accept Date: 14 November 2020
  • First Publish Date: 01 January 2021